Latest Insights - page 12 | BiopharmaTrend

Schrödinger Adds Eli Lilly’s AI Drug-Discovery Models to Its Molecular Design Platform

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its cloud-based molecular design environment, LiveDesign. The partnership allows existing Schrödinger clients to access Lilly’s internal models for molecular …

Continue ›››

AI-Unicorn Chai Discovery and Eli Lilly to Train Custom AI Models for Biologics Design

San Francisco-based Chai Discovery has partnered with Eli Lilly to integrate Chai’s molecular design platform into Lilly’s discovery workflows and develop a bespoke AI model trained on Lilly’s proprietary data, …

Continue ›››

Servier Signs €1B-Plus Multi-Target AI Drug Discovery Partnership With Iktos

Iktos and Servier have entered a multi-year, multi-target research collaboration under which Iktos will apply its AI-driven molecular design and automated synthesis platform to discover small-molecule drug candidates, while Servier …

Continue ›››

Eli Lilly Makes its AI Models Available to Biotech Sector via Benchling

Eli Lilly is making its AI/ML platform, TuneLab, broadly accessible through an integration with San-Francisco based Benchling, bringing models trained on over $1 billion worth of proprietary research data into …

Continue ›››

Medable Releases New AI Agent to Automate Trial Master File Processing

Palo-Alto based Medable has launched a new AI agent to automate the trial master file (TMF) process, one of the most labor-intensive components of clinical research operations. The announcement comes …

Continue ›››

GSK Licenses AI-Based Virtual Cell Models From Noetik in Five-Year Oncology Research Agreement

GSK has entered a five-year collaboration and licensing agreement with San Francisco–based Noetik to access AI foundation models focused on simulating human tumor biology in non-small cell lung cancer and …

Continue ›››

Eli Lilly Signs up to $950M AI-Guided Cancer Therapeutics Deal with InduPro

Eli Lilly has signed a multi-target discovery agreement with InduPro, a U.S.-based biotech focused on multispecific therapeutics, to pursue new cancer treatments using an AI-enabled membrane interactomics platform. The deal …

Continue ›››

OpenAI Lauches ChatGPT Health and Healthcare for Patients and Hospitals

OpenAI has introduced a new dedicated health interface within ChatGPT, ChatGPT Health, designed to personalize health-related interactions using user-linked medical records and wellness data. In addition to ChatGPT Health for consumers, OpenAI …

Continue ›››

Bayer Enters Three-Year AI Antibody Discovery Collaboration with Cradle

Bayer has entered a three-year collaboration with Cradle to integrate Cradle’s generative AI platform for protein engineering into Bayer's internal workflows for therapeutic antibody discovery and optimization. The agreement is …

Continue ›››

From Animals to Algorithms: How AI Brings Drug Testing Closer to Human Biology

Preclinical and nonclinical testing of drugs has traditionally relied on animal models to assess efficacy and toxicity before moving into human trials. However, these models raise ethical concerns and are …

Continue ›››

Somite AI Retitles as Cellular Intelligence in Pursuit of a Universal Virtual Cell Signaling Model

Founded in 2023 and based in Boston, Cellular Intelligence becomes the new identity of Somite AI, expanding toward large-scale, dynamic modeling of cell signaling. Alongside the rebrand, the company has …

Continue ›››

1910 Releases AI Model That Designs Cell-Permeable Macrocyclic Peptides

Boston-based 1910 (previously 1910 Genetics) has introduced a new AI model, PEGASUS, designed to create a class of drug molecules—macrocyclic peptides—that are notoriously difficult to engineer for use inside the …

Continue ›››